Background: SQ3370 is the first demonstration of the Click Activated Protodrugs Against
Cancer (CAPACTM) platform that uses click chemistry to activate drugs directly at tumor …

In the ever-evolving landscape of cancer research, immuno-oncology stands as a beacon of
hope, offering novel avenues for treatment. This study capitalizes on the vast repository of …

New antibodies–drug conjugate (ADC) payloads overcoming chemoresistance and killing
also poorly proliferating tumors at well-tolerated doses are much desired. Duocarmycins are …

Cancer treatments have recently shifted from broad-spectrum cytotoxic therapies to more
focused treatments, maximizing anti-cancerous activity while reducing toxicity to healthy …

Urothelial carcinoma is the second most frequent genitourinary malignancy. Despite the
poor prognosis, new treatment options have emerged and have expanded the therapeutic …

In the era of precision medicine, Antibody-Drug Conjugates (ADCs) have emerged as a
cutting-edge therapeutic strategy. These innovative compounds combine the precision of …

Abstract Antibody‐drug conjugates (ADCs), chemotherapeutic agents conjugated to an
antibody to enhance their targeted delivery to tumors, represent a significant advancement …

Antibody-Drug Conjugates (ADCs) represent an innovative class of potent anti-cancer
compounds that are widely used in the treatment of hematologic malignancies and solid …

Reinventing approved therapeutic proteins for a new dose, a new formulation, a new route
of administration, an improved safety profile, a new indication, or a new conjugate with a …

Small-molecule drugs have been employed for years as therapeutics in the pharmaceutical
industry. However, small-molecule drugs typically have short in vivo half-lives which is one …